/ /

  • linkedin
  • Increase Font
  • Sharebar

    Discern best surgical, medical therapy for ocular surface squamous neoplasia

    Treatment course may depend on lesion characteristics, potential patient compliance

    Miami—Though surgical or medical therapies are available to surgeons faced with treating ocular surface squamous neoplasia (OSSN), determining the appropriate therapy may not be so cut and dried.

    Excision with cryotherapy is successful but can result in limbal stem cell deficiency when tumors are large, and lesion recurrences can occur even with negative margins.

    Related: Swept-source OCT affords greater detailing in vitreous imaging

    Chemotherapy options work well but depend heavily on patient compliance with drop instillation.

    “Sometimes these cases are easy to resolve and sometimes not,” said Carol L. Karp, MD, professor of ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine. “Be ready to combine treatment options to cure the cancer.”

    Related: Exploring non-surgical therapy for periocular skin cancer

    Dr. Karp described a typical case of a 67-year-old woman who presented with a conjunctival and corneal lesion, which developed in the exposure zone. It had classic features that included leukoplakia, a mobile gelatinous limbal component, and an opalescent corneal lesion.

    “This is a typical OSSN,” she explained, adding that OSSN is the umbrella terminology for conjunctival and corneal dysplasia up to but not including squamous cell carcinoma.

    Recent: Femto-CKT procedure shows promise for keratoconus stabilization

    OSSN risk factors include ultraviolet light exposure in most cases, human papilloma virus, and immune deficiency, such as HIV.

    OCT in ocular surface oncology

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results